All In Biotech

Drug Trial Radar · NCT05838131

Study of CT071 Injection in RRMM or PPCL

A Clinical Trial to Explore the Safety and Efficacy of CT071 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

Last checked: Nov 19, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Actual

Start

Apr 28, 2023

Primary completion

Jul 2025

Study completion Jul 2025

Sponsor

Lead sponsor
Shanghai Changzheng HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CARsgen Therapeutics Co., Ltd.
First posted
May 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Clinical Trial to Explore the Safety and Efficacy of CT071 injection in Patients with Relapsed/Refractory Multiple Myeloma or Primary Plasma Cell Leukemia

Conditions

  • Multiple Myeloma
  • Primary Plasma Cell Leukemia

Interventions

  • Experimental: CAR-T cells InfusionDrug

    Biological: chimeric antigen receptor T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT after CT071 infusionTime frame: Assessed from the date of first dose of study treatment until 21~28 days
  2. AE of Neurotoxicity and cytokine release syndrome after CT071 infusionTime frame: From first dose of study drug adminisration to end of treatment (up to 12 months)
  3. Adverse Events (AE) after CT071 infusionTime frame: From first dose of study drug administration to end of treatment (up to 12 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Changzheng Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.